AMED is currently trading down over 23% in late afternoon trading after reporting Q4 results that didn’t impress a couple of the analysts following the company. Jeffries + Co. and Oppenheimer both downgraded the company following the resignation of the company’s CEO and the company’s fourth quarter miss. Analysts are questioning whether there is more to the CFO leaving, and if there are more problems to be uncovered. Analysts were particularly harsh, flipping from Buy to Sell ratings. AMED is currently trading at $31.02.